Share
Explore

Liraglutide Injection Market Is Expected To Generate A Revenue Of USD 4.4 billion By 2028

The latest market report published by Credence Research Inc. is “Global Liraglutide Injection Market: Growth, Future Prospects, and Competitive Analysis, 2016 – 2028”. The global liraglutide injection market generated revenue of around USD 4.4 billion in 2021 and is anticipated to grow a CAGR of over 9.3% during the forecast period from 2022 to 2028 to reach around USD 7.5 billion in 2028.
Liraglutide Injection is a synthetic glucagon-like peptide-I receptor agonist that combines diet and exercise to improve glycemic control in adults with type II diabetes. It can be taken alone or in conjunction with another anti-diabetic medication. Liraglutide is a GLP-1 receptor agonist that works similarly to glucagon. It is classified as a GLP-1 receptor agonist and is 97% homologous to the native GLP-1 by substituting arginine for lysine at position 34. It inhibits the production of hepatic glucose, slows gastric emptying, and stimulates the release of insulin from pancreatic beta cells in response to meals. It is marketed under the brand names Victoza and Saxenda. The increasing prevalence of type 2 diabetes globally is primarily driving the growth of the liraglutide injection market. The rising prevalence of obesity among young people worldwide and the growing preference for weight-loss treatments also contribute to the market's expansion. However, the severe side effects of liraglutide are expected to impede the market growth. Common side effects include gastroenteritis, hypoglycemia, kidney disorders (kidney failure), severe allergic reactions, gallbladder difficulties, and kidney stones.
The is bifurcated into type, application, and geography. The global market is categorized into types I and II based on the type. Based on the application, the market is segmented into hypoglycemic, weight loss, and others. The market is geographically divided into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa.
North America dominated the global liraglutide injection market in 2021, owing to rising obesity awareness, rapidly increasing healthcare expenditure, an aging population, an increase in lifestyle-related diseases, and a rise in obesity and obesity-related disease incidences in the region. The advanced R&D facilities and new drug developments by key regional players are driving demand for improved and cost-effective anti-obesity drugs, propelling the growth of the North American liraglutide injection market during the forecast period.
Liraglutide injection is a new type of diabetes medication that was developed by the pharmaceutical company, Novo Nordisk. It is a type 2 diabetes treatment that helps to control blood sugar levels by increasing the body's ability to produce insulin. This drug has been shown to be effective in treating type 2 diabetes and has received positive reviews from patients and doctors alike. However, Liraglutide injection is only available through prescription and is not yet available on the market as a generic medication.
Why to Buy This Report -
· The report examines the global liraglutide injection market by segment, current trends, drivers, restraints, opportunities, challenges, and market dynamics from 2016 to 2020, with 2021 as the base year and 2022-2028 as the projected period.
· The report includes information on the competitive landscape, such as how the market's key players perform on a global, regional, and country level.
· In-depth analysis of the global liraglutide injection market segmentation by type and application.
· The report contains comprehensive data for all factors, including CAGR, consumer purchasing trends, supply and demand, and import/export statistical data for major regional countries.
· The liraglutide injection industry report includes global, regional, and country-level market analysis, key market trends, major players analysis, market growth strategies, and key application areas.
About Us Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, nonlegislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task. Contact Us- Office No 3 Second Floor, Abhilasha Bhawan, Pinto Park, Gwalior [M.P] 474005 India sales@
Want to print your doc?
This is not the way.
Try clicking the ⋯ next to your doc name or using a keyboard shortcut (
CtrlP
) instead.